• Company
• An unexpected story by Organon and Viatris
• by Jan 28, 2022 05:58am

• Opinion
• [Reporter’s View] Ahead Kymriah’s NHIS negotiations
• by Eo, Yun-Ho Jan 28, 2022 05:57am

• Policy
• Publicized discussion on PAH reimbursement bears fruit
• by Choi-sun Jan 28, 2022 05:57am

• Policy
• Generics for Galvus will be listed next month
• by Kim, Jung-Ju Jan 28, 2022 05:57am

• Company
• The NOAC market with ₩230 billion is fluctuating
• by Kim, Jin-Gu Jan 27, 2022 05:44am

• Policy
• MNCs ask to “Innovate new drug reimbursement environment"
• by Lee, Jeong-Hwan Jan 27, 2022 05:43am

• Company
• Celltrion completes transfer of Takeda-acquired products
• by Ji Yong Jun Jan 27, 2022 05:43am

• Policy
• PVA guidelines are about to be revised
• by Lee, Hye-Kyung Jan 27, 2022 05:43am

• Policy
• The NHIS will begin research on improving the PVA system
• by Lee, Jeong-Hwan Jan 27, 2022 05:43am

• Company
• Sales of flu treatments have decreased significantly
• by Chon, Seung-Hyun Jan 27, 2022 05:42am